Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus GALLIUM GA 68 GOZETOTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus GALLIUM GA 68 GOZETOTIDE.
CIS-MDP vs GALLIUM GA 68 GOZETOTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical